Trial · NCT06513949
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Day 4 Oxygenation Index | Day 1 through Day 4 | (mean airway pressure x fraction of inspired oxygen \[FiO2\] x100)/ partial pressure of oxygen \[PaO2\] |
| Secondary | Biomarkers of injury and inflammation measured in bronchoalveolar lavage fluid | Day 4 | Interleukin(IL)-6 |
| Secondary | Biomarkers of injury and inflammation measured in plasma | Day 4 | Interleukin(IL)-6 |
| Secondary | Oxygenation index | Days 7 and 14 | (mean airway pressure x FiO2 x100)/PaO2 |
| Secondary | Oxygen saturation index | Days 4, 7, and 14 | (mean airway pressure x FiO2 x100)/peripheral oxygen saturation \[SpO2\] |
| Secondary | P:F ratio | Days 4, 7, and 14 | Ratio of partial pressure of arterial oxygen (P) to fraction of inspired oxygen (F) |
| Secondary | S:F ratio | Days 4, 7, and 14 | Ratio of the arterial oxygen saturation (S) to fraction of inspired oxygen (F) |
| Secondary | Sequential Organ Failure Assessment (SOFA) Score (range 0 [best] to 24 [worst]) | Days 4, 7, and 14 | Disease severity scale |
| Secondary | Time to blood presepsin level | Days 0-4 | Time from study consent to measurement completion of blood presepsin level via the PATHFASTTM instrument |
| Secondary | Cumulative incidence of run failures | Days 0-1 | Defined as not completing presepsin measurement between consent and infusion of study drug |
| Secondary | Cumulative incidence of protocol-specified exempt serious events | Days 1-28 | protocol-specified exempt serious events |
| Secondary | Cumulative incidence of grade 3 and 4 clinical and laboratory adverse events | Days 1-28 | Common Toxicity Criteria for Adverse Events version 5.0 |
| Secondary | Cumulative incidence of serious adverse events | Days 1-28 | Serious adverse events standard definition |
| Secondary | Cumulative incidence of adverse events of special interest | Days 1-28 | Adverse events of special interest for test article and bronchoalveolar lavage |
| Other | Ventilator-free Days | Days 1-28 | Days alive and free of invasive mechanical ventilation |
| Other | Mortality | Day 1-28 | All-cause mortality |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06513949/registered